Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio, USA.
J Infect Dis. 2021 Jul 15;224(2):326-331. doi: 10.1093/infdis/jiaa731.
Although atovaquone is effective in treating and preventing Pneumocystis pneumonia (PCP), its use is limited by nonlinear absorption and adverse events. The current study was undertaken to examine the activity of encochleated atovaquone (eATQ), a novel lipid-crystal nanoparticle formulation, in a mouse model of PCP. eATQ 100-200 mg was superior to commercially available atovaquone at 14 days in decreasing total Pneumocystis nuclei and asci. eATQ plus anidulafungin reduced nuclei significantly better than commercial atovaquone plus anidulafungin. eATQ is a novel formulation of atovaquone that warrants further evaluation for treatment and prevention of PCP.
虽然阿托伐醌在治疗和预防卡氏肺孢子虫肺炎（PCP）方面有效，但由于其非线性吸收和不良反应，其应用受到限制。本研究旨在通过卡氏肺孢子虫肺炎小鼠模型来检测包裹阿托伐醌（eATQ），一种新型脂质晶体纳米颗粒制剂的活性。在第 14 天，eATQ100-200mg 在减少总卡氏肺孢子虫核和囊包方面优于市售阿托伐醌。eATQ 加安尼芬净使核的减少显著优于商业阿托伐醌加安尼芬净。eATQ 是阿托伐醌的一种新型制剂，值得进一步评估其治疗和预防 PCP 的效果。
